References
- Dumont FJ. Alemtuzumab (Millenium/ILEX). Curr Opin Investig Drugs 2001;2:139–160.
- Keating MJ, Flinn I, Vinay J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–3561.
- Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
- Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768–773.
- Rieger K, Von Grunhagen U, Fietz T, et al. Efficacy and tolerability of alemtuzumab (Campath 1H) in the salvage treatment of B-cell chronic lymphocytic leukemiachange of regimen needed? Leuk Lymphoma 2004;45:345–349.
- Thieblemont C, Bouafia F, Hornez E, et al. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 2004;45:711–714.
- Rebello P, Cwynarski K., Varughese M, et al. Pharmacokinetics of Campath-1H in BMT patients. Cytotherapy 2001;3:261–267.
- Elter T, Molnar I, Kuhlmann J, et al. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma 2008;49:2256–2262.
- Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
- Montillo M, Tedeschi A, Migueletz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006;24:2337–2342.
- Cortelezzi A, Pasquini MC, Gardellini U, et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia(CLL): results of a prospective, single-arm multicentre study. Leukemia 2010;24:890–891.
- Montagna M, Montillo M, Avanzini MA, et al. Pharmacokinetics (PK) of alemtuzumab after subcutaneous (sc) administration for consolidation in patients with CLL. Haematologica 2009; 94(Suppl. 3):S71
- Mould DR, Baumann A, Kuhlmann J, et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007;64:278–291.